Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22164666 | 0.98 | NCF1 (0.48) | NCF1CA1CA2ALDH1A1PLG | |
| SCHEMBL23145045 | 0.86 | NCF1 (0.41) | NCF1CA1CA2ALDH1A1PLG | |
| SCHEMBL16977567 | 0.82 | NCF1 (0.52) | NCF1ALDH1A1LMNA | |
| SCHEMBL964176 | 0.82 | NCF1 (0.52) | NCF1ALDH1A1MEN1KMT2A | |
| SCHEMBL4632594 | 0.82 | ALDH1A1 (0.44) | NCF1CA1CA2ALDH1A1MEN1 | |
| SCHEMBL31336838 | 0.82 | NCF1 (0.46) | NCF1ALDH1A1PLGPLATLMNA | |
| Hydrochloric Acid SCHEMBL17711696 | 0.80 | NCF1 (0.50) | NCF1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11718043 | 0.80 | ALDH1A1 (0.43) | NCF1CA1CA2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL927894 | 0.80 | NCF1 (0.50) | NCF1ALDH1A1MEN1KMT2A | |
| SCHEMBL16508914 | 0.79 | CA1 (0.42) | NCF1CA1CA2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034094-B1 | PHOSPHODIESTERASE INHIBITORS AND USE | ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-115151253-B | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-116574099-A | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-115151253-A | Phosphodiesterase inhibitors and uses thereof | 南京征祥医药有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-4034094-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. (CN) | 2022-08-03 | — | — | EP | disclosed |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| WO-2021061803-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021061803-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2021-04-01 | — | — | WO | disclosed |
| WO-2020140001-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2020-07-02 | — | — | WO | disclosed |
| US-8586612-B2 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| CN-101080388-B | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND | 2010-12-22 | — | — | CN | disclosed |
| EP-1828131-B1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-06-04 | — | — | EP | disclosed |
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| CN-101080388-A | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828131-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063722-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A3, ATP2A2 | NCF1 4431/4885CA1 3827/4885CA2 844/4885 |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | ENPP1, ENPP3, PDE4A | NCF1 307/4885CA1 4735/4885CA2 3011/4885 |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | NCF1 978/4885CA1 4390/4885CA2 2126/4885 |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | NCF1 978/4885CA1 4390/4885CA2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.